Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Fuji
McKesson
Boehringer Ingelheim
AstraZeneca
Citi
McKinsey
Daiichi Sankyo
US Army
QuintilesIMS

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,015,819

« Back to Dashboard

Summary for Patent: 6,015,819
Title: Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
Abstract:A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
Inventor(s): Gluchowski; Charles (Danville, CA), Forray; Carlos C. (Paramus, NJ), Chiu; George (Bridgewater, NJ), Branchek; Theresa A. (Teaneck, NJ), Wetzel; John M. (Elmwood Park, NJ), Hartig; Paul R. (Pennington, NJ)
Assignee: Synaptic Pharmaceutical Corporation (Paramus, NJ)
Application Number:08/244,354
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,015,819

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,015,819

PCT Information
PCT FiledNovember 12, 1993PCT Application Number:PCT/US93/10950
PCT Publication Date:May 26, 1994PCT Publication Number: WO94/10989

International Patents Family Members for US Patent 6,015,819

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 7684894 ➤ Subscribe
Canada 2148839 ➤ Subscribe
Canada 2187773 ➤ Subscribe
European Patent Office 0667769 ➤ Subscribe
European Patent Office 0758894 ➤ Subscribe
Israel 107581 ➤ Subscribe
Israel 110902 ➤ Subscribe
Australia 5602994 ➤ Subscribe
Israel 113248 ➤ Subscribe
Japan H08506800 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Fuji
Dow
Deloitte
Express Scripts
Daiichi Sankyo
Cerilliant
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot